LAVA Therapeutics N.V. (LVTX) Misses Q3 EPS by 13c

LAVA Therapeutics N.V. (NASDAQ: LVTX) reported Q3 EPS of ($0.46), $0.13 worse than the analyst estimate of ($0.33).

For earnings history and earnings-related data on LAVA Therapeutics N.V. (LVTX) click here.

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy